Enforcement Report - Week of March 1, 2023
Boehringer Ingelheim has reported results from the RE-SPECT CVT study, which investigated the safety and efficacy of Pradaxa (dabigatran etexilate) and dose-adjusted warfarin in cerebral venous and dural sinus thrombosis (CVT) patients.
Warfarin Monitors: FDA Warns of Inaccurate Results
Every two seconds a person is affected by thrombosis. Blood clots forming and blocking the circulation in veins and arteries is the number one cause of death globally, with complications such as myocardial infarction and stroke accounting for the majority of fatalities. Patients at risk of developing blood clots receive preventive treatment with antithrombotic agents often called blood-thinning medicines such as Warfarin, aspirin and the later introduced NOACs.
Opdivo is emerging as foundational drug across multiple tumors and multiple lines of therapy.
More than four in five stroke patients with a history of heart rhythm problems didn’t get any blood thinners, or didn’t take enough to help prevent a stroke before they had one, a U.S. study suggests.
The cardio sector continues to roll out new treatments to keep our blood pumping smoothly, cholesterol at bay and CV risk at a minimum. And as it does, marketers are striving to find a balance between brands already nestled in the market and the highly anticipated wave of cardio products ready to ink invitations to their launch parties.
When Loren Peters arrived in the emergency room in October 2013, bruises covered his frail body, and blood oozed from his gums.nnThe 85-year-old had not been in a fight or fallen down. Instead, he had been given too much of a popular, decades-old blood thinner that, unmonitored, can turn from a lifesaver into a killer.
FDA gives Boehringer`s Pradaxa antidote a boost with fast-track review